NI 43-101 Technical Report targeting significant increase in mine life expected Q2 2018 TORONTO, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Ascendant Resources Inc. (TSX:ASND) (OTCQX:ASDRF) (FRA:2D9) ("Ascendant" or the "Company”) announces the results from an additio...Read More
Positive Free Cash Flow for Q4 2017 with US$8.0 million in cash exiting 2017Record tonnes milled in December; production increased by 81% since January 2017Guidance for 2018: Free Cash Flow of US$14-$20 million; EBITDA of US$32-$40 million TORONTO, Jan. 11, 2018 (GLOBE NEWSWIRE) -- Ascendant...Read More
COPENHAGEN, Denmark, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today provided an update on its rare disease endocrinology pipelin...Read More
COPENHAGEN, Denmark, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced it has reached its target enrollment in the phase...Read More
COPENHAGEN, Denmark, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced that the company will participate in an upcoming i...Read More
Adjusted EBITDA1 of $1.6 million in NovemberRecord tonnes hoisted in November and Q4 production gains expected to drive robust operating and financial results in 2018Milled production tonnes up 67% year to date TORONTO, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Ascendant Resources Inc. (TSX:ASND)...Read More
TORONTO, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Ascendant Resources Inc. (TSX:ASND) (OTCQX:ASDRF) (FRA:2D9) ("Ascendant" or the "Company”) reports that operations at its El Mochito mine in Honduras are continuing normally despite uncertainty following the General Elections h...Read More
COPENHAGEN, Denmark, Nov.21, 2017(GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced that the company will participate in an upcoming inves...Read More
- Phase 3 Program for TransCon Growth Hormone Advances and TransCon PTH Enters the Clinic - - Conference Call Today at 4:30 p.m. Eastern Time - COPENHAGEN, Denmark, Nov.16, 2017(GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCo...Read More
Adjusted EBITDA1 of $1.3 million in OctoberMilled production increased to 2,184 tpd; up 67% year to dateNew fleet arrivals to drive production growth in Q4 2017 and 2018 TORONTO, Nov.14, 2017(GLOBE NEWSWIRE) -- Ascendant Resources Inc. (TSX:ASND) (OTCQX:ASDRF) (FRA:2D9) ("Ascendant" or the "Comp...Read More
Highlights Include: Net income of $821,000 and $0.01/shareThird consecutive month of positive adjusted EBITDA1; $2.4 million total for Q3 201775% increase in revenue versus Q2 2017Operating cash flow before changes in working capital of $2.3 million; Free cash flow expected before the end of Q4M...Read More
TORONTO, Nov.02, 2017(GLOBE NEWSWIRE) -- Ascendant Resources Inc. (TSX:ASND) (OTCQX:ASDRF) (FRA:2D9) ("Ascendant" or the "Company") announced today that it plans to release its third quarter 2017 results after the market close on Monday, November 13, 2017. Management will host a conference call...Read More
COPENHAGEN, Denmark, Nov.02, 2017(GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced that the company will hold a conference call and live...Read More
Milled production for Q3 increased by 17% against Q2 2017 averaging 1,934 tpd; September milled production increased by 8% versus August 2017 averaging 2,055 tpdFree cash flows expected imminentlyQ3 performance expected to support a strong Q4 and year-end exit rate that should drive robust 2018...Read More
TORONTO, Oct. 16, 2017 /CNW/ - Chris Buncic, President and CEO, Ascendant Resources Inc. (ASND), joined Shaun McIver, Chief Client Officer, Equity Capital Markets, TMX Group, to open the market. Ascendant Resources Inc. is a mining company focused on its producing El Mochito zinc, silver and lead...Read More
ZnEq grades proving to be consistently above current mining gradeKey Highlights*: (true and apparent widths): Exploration Areas in 2017 Infill HolesHOLE 10875 - 5.5m at 45.5% ZnEq, 5.2% zinc, 2.7% lead, 2,297 g/t silver and 0.98% copperHOLE 10887 - 23.4m at 7.7% ZnEq....Read More
TORONTO, Sept.28, 2017(GLOBE NEWSWIRE) -- Ascendant Resources Inc. (TSX:ASND) (OTCQX:ASDRF) (FRA:2D9) ("Ascendant" or the "Company") is pleased to announce the appointment of Ms. Petra Decher, CPA, CA to the Company's Board of Directors and Mr. Stephen Shefsky to the position of Lead Director of...Read More
COPENHAGEN, Denmark, Sept.27, 2017(GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 3,800,000 American Depositary Shares ("ADSs"), each of which represents one ordinary share of As...Read More
COPENHAGEN, Denmark, Sept.26, 2017(GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, announced today that it has dosed subjects in a phase 1 trial of Tran...Read More
COPENHAGEN, Denmark, Sept.26, 2017(GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $125,000,000 of American Depositary Shares ("ADSs"), each of which represents one ordina...Read More